MiR-181c acts as an oncogenic factor and activates the Wnt/β-catenin pathway by targeting Wnt inhibitory factor 1 (WIF1), which subsequently promotes DDP resistance in NSCLC cells [172]. This evidence concerns the gene WIF1 and non-small cell lung carcinoma.